Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Regentis BiomaterialsRGNT -2.48%14 Net Cash per Share is $0.87 as of Dec. 2025. GuruFocus rates RGNT with a GF Score™ of 14/100. The stock has 2 warning signs investors should review. Among 295 Medical Devices & Instruments companies, Regentis Biomaterials ranks better than 88.14% on this metric.
The historical rank and industry rank for Regentis Biomaterials's Net Cash per Share or its related term are showing as below:
RGNT'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.24 Med: 7.75 Max: 7.75
Current: 2.28
During the past 6 years, the highest Price-to-Net-Cash Ratio of Regentis Biomaterials was 7.75. The lowest was 2.24. And the median was 7.75.
RGNT's Price-to-Net-Cash is ranked better than 88.14% of 295
companies
in the Medical Devices & Instruments industry
Industry Median: 9.38
vs RGNT: 2.28
Regentis Biomaterials (AMEX:RGNT) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Regentis Biomaterials Net Cash per Share Related Terms
Regentis Biomaterials Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Regentis Biomaterials's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RGNT vs BNGO, LUCY, CUPR: Net Cash per Share Comparison
For the Medical Instruments & Supplies subindustry, Regentis Biomaterials's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regentis Biomaterials Price-to-Net-Cash vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Regentis Biomaterials's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Regentis Biomaterials's Price-to-Net-Cash falls into.
Regentis Biomaterials Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Regentis Biomaterials's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regentis Biomaterials (RGNT) has a Net Cash per Share of $0.87 as of Dec. 2025. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Regentis Biomaterials and its competitors. According to the industry distribution chart, Regentis Biomaterials ranks #35 out of 295 companies in the Medical Devices & Instruments industry, placing it in the top 11.9%.
Is Regentis Biomaterials' Net Cash per Share too high?
Regentis Biomaterials' current Net Cash per Share is $0.87. The Medical Devices & Instruments industry median Net Cash per Share is 9.38. Regentis Biomaterials' value of $0.87 is 90.7% below this industry median. Based on the distribution chart, Regentis Biomaterials ranks #35 out of 295 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Regentis Biomaterials has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Regentis Biomaterials' Net Cash per Share compare to BNGO and LUCY?
According to the Medical Devices & Instruments industry distribution chart, Regentis Biomaterials ranks #35 out of 295 companies for Net Cash per Share. This places Regentis Biomaterials in the top 12% of its industry — outperforming the majority of peers. The industry median Net Cash per Share is 9.38. Regentis Biomaterials' value of $0.87 is 90.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Medical Devices & Instruments company?
The median Net Cash per Share among Medical Devices & Instruments companies is 9.38, based on 295 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regentis Biomaterials's current Net Cash per Share of $0.87 is 90.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Regentis Biomaterials and its competitors. For the Medical Devices & Instruments industry, the median Net Cash per Share is 9.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regentis Biomaterials's current Net Cash per Share is $0.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regentis Biomaterials stock overvalued right now?
Regentis Biomaterials (RGNT) has a current Net Cash per Share of $0.87. The current Net Cash per Share is $0.87 and 90.7% below the Medical Devices & Instruments industry median of 9.38. Regentis Biomaterials' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Regentis Biomaterials (RGNT), the current Net Cash per Share is $0.87 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.
14GF Score
Get the complete analysis for RGNT
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGNT has been successfully added to your 
